A 69-year-old man presented with multiple nodules on the spleen and liver that had been detected by computed tomography (CT). A liver tumor biopsy was performed, and the patient was diagnosed to have histiocytic sarcoma (HS). Splenectomy was performed, and the chemosensitivity of the spleen tumor was measured using the collagen gel droplet-embedded culture drug sensitivity test (CD-DST). Hepatic arterial infusion chemotherapy was administered, based on the results of the CD-DST. The patient achieved complete remission (CR) after this therapy and remained alive without recurrence at the final follow-up. This is the first known case of CR in response to chemotherapy for advanced splenic HS.
Introduction
Histiocytic sarcoma (HS) was first described by Mathe et al. (1) as a group of malignant neoplastic cells that displayed the histological features of connective tissue macrophages. The largest study of HS reported to date included only 18 patients (2) among which primary splenic HS was extremely rare. Most patients with HS show a limited response to chemotherapy, and a high mortality rate is the usual clinical outcome (2) (3) (4) (5) (6) (7) . No effective chemotherapy for advanced cases of primary splenic HS with liver inversion has so far been reported (2, (8) (9) (10) (11) , nor has a standard regimen been established. This report presents a case showing a complete response of primary splenic HS to chemotherapy that was selected by a chemosensitivity test using the colla- (Fig. 1A, B) . A fluorodeoxyglucose-positron emission tomography (FDG-PET)/CT scan showed increased 18 F-FDG uptake in these multifocal nodules of the spleen and the liver (the maximum standardized uptake value (SUV) of the liver mass was 22.5, and that of the spleen was 13.8; Fig. 1C, D) . Bone marrow aspiration and a biopsy were normocellular and there was no evidence of any involvement with HS or other hematologic neoplasm. An ultrasoundguided percutaneous needle liver tumor biopsy (USGLB) was performed, and the specimens were histochemically analyzed (Fig. 2) . Hematoxylin and eosin staining indicated eosinophilic cytoplasm and round to oval nuclei ( Fig. 2A ). An immunohistochemical analysis indicated these cells to be positive for CD163 (Fig. 2B ) and CD68 (phosphoglucomutase-1; Fig. 2C ). These cells were negative for markers of Langerhans cells (CD1a, Langerin, S-100), follicular dendritic cells (CD21, CD35), and interdigitating dendritic cells (S-100). In addition, these cells were also negative for CD34, von Willebrand factor, paired box protein 5, fascin, CD43, CD61, CD42b, and factor XIIIa. These results suggested a diagnosis of HS. However, it was not possible to determine whether or not the splenic tumor was also HS, since it is difficult to histologically diagnose a splenic tumor by a biopsy. Moreover, it is difficult to identify suitable chemotherapeutic drugs for HS, even if the splenic tumor was HS. The reported regimen for a neoplasm of an unknown primary site was initiated, which involved two cycles of paclitaxel/carboplatin/etoposide (12) . This therapy was considered to be effective, because the volumes of the liver and spleen tumors were considered to have decreased on CT scans. However, this regimen could not be continued because the patient demonstrated grade 4 neutropenia, as well as grade 2 peripheral neurotoxicity, according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v3.0. Splenectomy was performed to identify a more appropriate regimen of chemotherapy, and to histologically diagnose the splenic tumor. The histological findings of the splenic tumor were compatible with HS, and the splenic tumor and liver metastasis were both diagnosed as HS. The chemosensitivity of the splenic tumor cells was evaluated using the CD-DST. This assay determines the antitumor effect of a drug based on a ratio of relative growth rate, which was calculated by the ratio of the total volume of the colony that was in contact with (T), or not in contact with (C) the drug, according to the following formula: T/C× 100%. A T/C ratio of <50% indicated high sensitivity, and a T/C ratio of 50-60% was considered to indicate moderate sensitivity (13) . This assay indicated that the tumor cells were sensitive to mitomycin C (MMC) and etoposide (VP-16; Fig. 3 ). Therefore, these two drugs were selected for the chemotherapeutic regimen. Fortunately, the FDG-PET/CT data revealed the metastatic HS tumors were localized only in the liver and spleen of this patient (Fig. 4A) . Therefore, hepatic arterial infusion chemotherapy (HAI) was administered via a subcutaneous reservoir port, and chemotherapy was performed using six cycles of MMC/VP-16. The patient received 8 mg of MMC with lipiodol via the subcutaneous reservoir port on the first day of the therapy. VP-16, 60 mg/ m 2 /day was then injected using a 2-hour infusion via the subcutaneous reservoir port on days 8-12. FDG-PET/CT showed a remarkable improvement after this chemotherapy (Fig. 4B) . This transarterial hepatic chemotherapy via a subcutaneous reservoir port did not exacerbate the peripheral neuropathy that had occurred during the first systemic chemotherapy. Moreover, the neutropenia was not at a serious level, namely within grade 2 according to CTCAE.
The patient was still alive, with no recurrence following a 3.5-year follow-up after the chemotherapy. This patient had a complete response (CR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) guideline version 1.1 (14) .
Discussion
This is the first report of a patient with primary splenic HS that achieved CR as a result of chemotherapy. HS has been defined as a malignant proliferation of cells showing morphological and immunophenotypic features similar to those of mature tissue histiocytes (3). The term "histiocytic" was used as a definition of cells in various states of reactive and neoplastic proliferation, including histiocytic lymphoma, malignant histiocytosis, and histiocytic medullary reticulosis. However, the majority of cases that were reported as HS were of non-histiocytic origin. A "true" HS is rare, and it usually developes in the lymph nodes, skin, and gastrointestinal tract (2, (4) (5) (6) (7) . Primary splenic HS is considered to be even rarer, and it has been estimated that only 17% of "HS" patients are "true" HS patients according to a large-scale lished as a new macrophage-related differentiation marker, which is a more specific marker of HS than histiocyterelated molecules (4), and this case was consistent with these immunohistochemical findings.
Most patients with HS usually show a poor prognosis due to frequent dissemination and the poor response of HS to chemotherapy (2-7). In particular, the prognosis of patients with primary splenic HS with liver metastasis is extremely poor due to hepatic failure, even for patients treated with multidisciplinary therapy (2, (8) (9) (10) (11) . The first round of chemotherapy that was performed in the current case was systemic chemotherapy, the effect of which was limited, and it was difficult to continue the treatment due to complications. A more effective chemotherapeutic regimen was therefore required. CD-DST is a useful tool for the design of tailormade chemotherapeutic regimens in cases of rare tumors (15) . Therefore, a CD-DST was conducted using tissue specimens from the splenectomy of this patient. The results of the CD-DST analysis indicated the selection of chemotherapy with MMC/VP-16, to which the tumor was judged to be moderately sensitive. The patient was therefore treated with six cycles of MMC/VP-16 following which CR, according to RECIST version 1.1 for patients with advanced HS, was obtained. Splenectomy may not always be considered an option for a patient at an advanced stage of HS due to unexpected adverse events, particularly the possibility of bleeding as a result of thrombocytopenia, which is considered to be a common complication of HS. However, since CD-DST is potentially very useful and important for identifying a suitable regimen of chemotherapeutic drugs, it may be necessary to consider obtaining spleen tissue samples even in patients with advanced HS.
Factors other than the CD-DST analysis could also be considered to have contributed to the achievement of CR in the current patient. A splenectomy was performed, thus allowing for a resection of the main tumor to obtain an early diagnosis of the liver and spleen tumors. The tumors were localized to the spleen and the liver, and, after resection of the spleen, the tumors were only localized to the liver. This liver localization allowed for treatment with HAI. Finally, intermittent HAI was administered via the subcutaneous reservoir port, which is also used as a treatment for metastatic liver cancer (16) . This treatment can deliver a high concentration of chemotherapeutic drugs, and is expected to be more efficient against liver tumors. This point was considered to be advantageous in the current case because the tumor was considered to be only moderately sensitive to the drugs selected based on the CD-DST. HAI is not only advantageous in comparison to systemic chemotherapy in terms of efficacy, but also in terms of reducing adverse events (16) , because the chemotherapeutic drugs would be first metabolized by liver cells and then move to the whole body. In fact, the adverse events due to HAI could be well controlled in this patient, which thus made it possible to continue this chemotherapeutic regimen. This is the first report of a case of advanced primary splenic HS in which CR was achieved by efficient chemotherapy. A CD-DST analysis is useful for identifying the suitable drugs for chemotherapy, and the resection of the main tumor in the spleen as well as HAI are factors that are considered to enhance the effects of the chemotherapy. It may thus be necessary to consider obtaining tumor tissue to perform a CD-DST analysis, even from patients with advanced HS. However, the accumulation and analyses of additional cases are required to conduct a precise evaluation of CD-DST and HAI for patients with HS.
